Anixa Biosciences (ANIX) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunic (IMUX) has outperformed Anixa Biosciences (ANIX) over the past year, losing 15.8% versus a loss of 34.5%. Over five years, ANIX leads with a -33.7% price change compared with -91.3% for IMUX. Immunic is the larger company by market cap ($103.2 million vs $101.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | IMUX |
|---|---|---|
| Share price | $2.91 | $7.56 |
| Market cap | $101.16M | $103.15M |
| 1-day change | -1.36% | -0.92% |
| YTD return | -6.73% | +41.57% |
| 1-year return | -34.46% | -15.81% |
| 5-year return | -33.71% | -91.28% |
| EPS (TTM) | $-0.32 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $17.43 |
| 52-week low | $2.32 | $5.06 |
| Distance from 52-week high | -46.70% | -56.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +235.05% | +469.97% |
| Average volume | 302.95K | 284.68K |
| Shares outstanding | 34.76M | 13.64M |
| Employees | 4 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed ANIX by 18.6 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Healthcare · Biotechnology · 100 employees
ANIX vs IMUX FAQ
Which is bigger, Anixa Biosciences or Immunic?
Immunic (IMUX) is larger, with a market capitalization of $103.15M compared with $101.16M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -34.46% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Immunic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.